Skip to content

Latham to Lead Week’s Only IPO Expected To Top $50M

Loeb & Loeb partner Fran Stoller was quoted on recent IPO activity within the healthcare and life sciences sectors. Although 2015’s IPOs have been disappointing overall, “biotech and life sciences in general have always been a different story,” said Stoller. “With the substantial increase in M&A activity, investors see a big payout. Companies go public, and all Big Pharma companies are looking for pipeline and early-stage products.”

Click here to read the article.